1月14日,疫苗企业摩德纳(MRNA)股价盘中大跌5.01%,引发市场广泛关注。
摩德纳公司此前将2025年全年销售预期下调10亿美元,旨在削减成本。该公司2025年收入预计将低于之前预期,主要由于新冠疫苗需求下降,同时由于削减研发资金,预计公司新疫苗产品上市进度或将放缓。
摩德纳的新冠疫苗在2022年和2023年带来了巨大收益,但随着疫情趋缓,需求正在大幅萎缩。该公司正加紧转型,推进如呼吸道合胞病毒(RSV)疫苗等新产品的市场化。不过,由于削减研发预算,新产品推向市场的进度或将放缓。此外,摩德纳在中国建厂进展不确定,也对业务增长构成隐忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.